Swiss drugmaker Roche signalled its ambition to join Eli Lilly and Novo Nordisk at the top of the booming weight-loss market ...

Roche expects to bring its obesity drug candidates to market by 2028, with projected sales of over 3 billion Swiss francs. Roche aims to cut drug development costs by 20% and reduce time to Phase 3 ...

Roche Holding AG will move an experimental obesity shot into late-stage trials next year in a bid to challenge leaders in the ...

Roche has agreed to buy U.S. biotech firm 89bio for up to $3.5 billion, joining a race to offer new liver disease treatments ...

Switzerland’s new process to speed up patient access to the latest drugs hit its first major hurdle in a clash with Roche.

Roche and Zealand Pharma in March struck a deal worth up to $5.3 billion to co-develop and co-commercialize amylin analog petrelintide as a potentially "next generation" weight loss drug. Executives ...

The pharmaceutical company said that giredestrant in combination with everolimus significantly improved progression-free ...

At its Pharma Day, Swiss pharmaceutical giant Roche Holdings AG (OTC:RHHBY) outlined five priority therapeutic areas: neurology, oncology and hematology, immunology, ophthalmology, and cardiovascular, ...

COPENHAGEN, Denmark — The ballooning obesity drug market may have a new contender after Roche struck a $5.3 billion deal to develop Danish biotech Zealand Pharma's "next generation" weight loss ...